Brisbane-based Factor Therapeutics (ASX:FTT), a company developing therapeutics for advanced wound care, has announced that its Phase 2 clinical trial VF00102 for the treatment of venous leg ulcers (VLU) is approaching the end of its treatment phase.
“Since finalising recruitment in July, the study has progressed to schedule and there are now only eight patients left to complete treatment," said CEO Dr Ros Wilson.
"We expect the last patient to have their final treatment visit in the first week of October, a key milestone for the study as it then triggers a final round of data cleaning and quality checks before top-line results can be analysed in November.”
The company said its is currently targeting top-line data release in mid-November. It says it is also progressing partnering discussions in addition to regulatory preparation for both CE Mark in Europe and Phase 3 discussions with the US FDA.